| Study characteristics |
| Methods |
Randomised 2:1, open‐label, non‐comparative, multicentre |
| Participants |
106 randomised. First‐line glioblastomas |
| Interventions |
Vandetanib + Stupp protocol vs no vandetanib + Stupp protocol |
| Outcomes |
OS: 16.6 vs 15.9 months (P = 0.8, HR not available) PFS: 7.7 vs 6.2 months (HR not available) PFS12: 0.25 vs 0.39 Toxicities: mostly haematological – 4.3% clots |
| Notes |
Used MacDonald criteria for radiological assessments |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Low risk |
“patients were randomly assigned 2:1 at registration to receive RT and temozolomide…” |
| Allocation concealment (selection bias) |
High risk |
Not concealed. Open‐label trial |
| Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
Not concealed. Open‐label trial |
| Blinding of outcome assessment (detection bias)
All outcomes |
Unclear risk |
Uncertain |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
13 patients registered but did not proceed to randomisation. |
| Selective reporting (reporting bias) |
Low risk |
All prespecified endpoints reported. |
| Other bias |
Low risk |
|
